Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75

[...]we investigated BA.2.75 neutralisation by antibodies induced after vaccination or breakthrough infection during the delta (October, 2021, to January, 2022) or early omicron (February–May, 2022, dominated by BA.1 and BA.2) waves in Germany. [...]we identified bebtelovimab (also known as LYCoV-1404) and the cilgavimab–tixagevimab antibody combination as treatments for BA.2.75-infected individuals. [...]our data confirm and extend the findings of two recent studies6,7 and provide evidence that three vaccine doses are required to induce potent neutralising activity against BA.2.75, similar to what has been shown for other omicron sublineages.8–10 AK, IN, SP, and MH conduct contract research (testing of vaccine sera for neutralising activity against SARS-CoV-2) for Valneva unrelated to this work.